Epigenetic priming of CDKN2A/p16INK4a drives a proteostatic shift toward protective amyloid-like aggregation as a senescence-associated containment mechanism

Andre Yamada· Mar 21, 2026

$Mechanism: Age-related CDKN2A hypomethylation increases p16INK4a, which then orchestrates a proteostasis shift towards protective amyloid-like aggregation of damaged proteins. Readout: Readout: Targeted demethylation of CDKN2A increases p16INK4a protein levels by at least 2-fold and insoluble, Thioflavin-T-positive protein fraction by at least 30%, while aggregate disruption exacerbates SASP.$

Hypothesis

Core idea: Age‑dependent DNA hypomethylation at the CDKN2A promoter leads to chromatin opening, increased p16^INK4a expression, and a concomitant re‑programming of the proteostasis network that favors the formation of ordered, amyloid‑like protein aggregates as a sequestration strategy for irreversibly damaged proteins.

Mechanistic link:

p16^INK4a, beyond its CDK‑inhibitory function, binds to the nuclear lamina and recruits histone‑acetyltransferases (e.g., p300) that locally increase H3K27ac, creating a permissive chromatin environment for genes encoding aggregation‑prone chaperones such as DNAJB6 and HSPB1.
This transcriptional shift raises the intracellular concentration of “holdase” chaperones that can nucleate the conversion of misfolded proteins into β‑sheet‑rich assemblies, a process akin to functional amyloid formation.
Concurrently, p16‑mediated CDK4/6 inhibition reduces phosphorylation of nucleophosmin (NPM1), promoting its translocation to nucleoli where it acts as a scaffold for phase‑separated condensates that mature into Thioflavin‑T‑positive aggregates.

Testable predictions:

In human fibroblasts, targeted demethylation of the CDKN2A promoter (using dCas9‑TET1) will increase p16^INK4a protein levels by ≥2‑fold and concomitantly raise the insoluble, Thioflavin‑T‑positive fraction of total protein by ≥30% compared with control.
Knock‑down of p16^INK4a (siRNA) in the same cells will abolish the aggregate increase despite promoter demethylation, and will sensitize cells to proteotoxic stress (e.g., MG‑132) as measured by elevated caspase‑3/7 activity.
Pharmacological disruption of aggregates (using the amyloid‑breaker EGCG) in p16‑high senescent cells will exacerbate the senescence‑associated secretory phenotype (SASP) – higher IL‑6 and IL‑8 secretion – and reduce clonogenic survival, indicating that aggregates are protective rather than deleterious.

Falsifiability: If aggregate formation does not change with p16^INK4a modulation, or if dissolving aggregates improves cellular fitness without increasing SASP, the hypothesis would be refuted.

Broader implication: This reframes p16^INK4a‑driven senescence not merely as a cell‑cycle arrest program but as an adaptive proteostatic response that sacrifices proliferative capacity to sequester harmful protein species, offering a new lens for interventions targeting age‑related proteotoxicity.

References:

Hypothesis

Mechanistic link:

p16^INK4a, beyond its CDK‑inhibitory function, binds to the nuclear lamina and recruits histone‑acetyltransferases (e.g., p300) that locally increase H3K27ac, creating a permissive chromatin environment for genes encoding aggregation‑prone chaperones such as DNAJB6 and HSPB1.

This transcriptional shift raises the intracellular concentration of “holdase” chaperones that can nucleate the conversion of misfolded proteins into β‑sheet‑rich assemblies, a process akin to functional amyloid formation.

Concurrently, p16‑mediated CDK4/6 inhibition reduces phosphorylation of nucleophosmin (NPM1), promoting its translocation to nucleoli where it acts as a scaffold for phase‑separated condensates that mature into Thioflavin‑T‑positive aggregates.

Testable predictions:

In human fibroblasts, targeted demethylation of the CDKN2A promoter (using dCas9‑TET1) will increase p16^INK4a protein levels by ≥2‑fold and concomitantly raise the insoluble, Thioflavin‑T‑positive fraction of total protein by ≥30% compared with control.

Knock‑down of p16^INK4a (siRNA) in the same cells will abolish the aggregate increase despite promoter demethylation, and will sensitize cells to proteotoxic stress (e.g., MG‑132) as measured by elevated caspase‑3/7 activity.

Pharmacological disruption of aggregates (using the amyloid‑breaker EGCG) in p16‑high senescent cells will exacerbate the senescence‑associated secretory phenotype (SASP) – higher IL‑6 and IL‑8 secretion – and reduce clonogenic survival, indicating that aggregates are protective rather than deleterious.

Falsifiability: If aggregate formation does not change with p16^INK4a modulation, or if dissolving aggregates improves cellular fitness without increasing SASP, the hypothesis would be refuted.

References: